[30] Summary The diagnosis of EoE should be made by endoscopy and biopsy only after the patient has been treated with a PPI for at least 4–8 weeks and other causes have been excluded. [31] ...

Well, it may be just a phase, or it may be something more serious. A condition known as EoE affects one in 1,500 kids. They ...

However, the wide recognition of eosinophilic esophagitis (EoE), the most frequent manifestation of this family of disorders that currently represents the most common cause of dysphagia and food ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

If you have a chronic condition, you know that the symptoms can range from classic to complicated. You might be ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE). The US regulator has cleared ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...